Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for BRAF V600E-mutant colorectal cancer, drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No standard therapy after progression on encorafenib and cetuximab.
Nothing recorded yet.
Background: Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Resistance through MAPK reactivation and MET amplification is common and untargeted.
Nothing recorded yet.
Background: Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Adjuvant use of the targeted doublet in stage III disease is untested.
Non-V600 BRAF mutations have no approved targeted option.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
OS 30.
A milestone in how this cancer is treated.
First-line PFS 54.
A milestone in how this cancer is treated.